|Security||UBX / Unity Biotechnology, Inc. (91381U101)|
|Institutional Shares||9,310,206 - 22.00%|
|Common Shares Outstanding||42,314,738 shares (as of 2018-06-30)|
|Institutional Value||$ 138,652,000 USD|
Institutional Stock Ownership and Shareholders
Unity Biotechnology, Inc. (NASDAQ:UBX) has 38 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9,310,206 shares.
Largest shareholders include
Baillie Gifford & Co, EcoR1 Capital, LLC, Partner Fund Management, L.P., NF Trinity Capital (Hong Kong) Ltd, Goldman Sachs Group Inc, Partner Investment Management, L.P., Redmile Group, LLC, BlackRock Inc., Capital World Investors, and Artal Group S.A..
Unity Biotechnology, Inc. (NASDAQ:UBX) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
|Laurion Capital Management LP||127,949||1,927|
|VANGUARD GROUP INC||112,532||1,695|
|AMERICAN INTERNATIONAL GROUP INC||3,288||50|
|SCHWAB CHARLES INVESTMENT MANAGEMENT INC||20,480||309|
|Catalyst Capital Advisors LLC||476||7|
|NF Trinity Capital (Hong Kong) Ltd||608,060||9,157|
|NORTHERN TRUST CORP||54,651||823|
|UBS Group AG||8,111||122|
|BANK OF AMERICA CORP /DE/||899||13|
|GOLDMAN SACHS GROUP INC||535,686||8,068|
|BANK OF MONTREAL /CAN/||36||1|
|Legal & General Group Plc||748||11|
|GEODE CAPITAL MANAGEMENT, LLC||56,287||847|
|GILDER GAGNON HOWE & CO LLC||20,000||301|
|Redmile Group, LLC||250,400||3,771|
|Dean Capital Investments Management, Llc||36,036||543|
|Capital World Investors||219,489||3,306|
|CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM||7,724||116|
|Alyeska Investment Group, L.P.||75,883||1,143|
|Partner Investment Management, L.P.||308,764||4,079|
|JP Morgan Chase & Co||1,025||15|
|EcoR1 Capital, LLC||1,680,644||25,310|
|WELLS FARGO & COMPANY/MN||818||12|
|STATE STREET CORP||40,100||604|
|NEW YORK STATE COMMON RETIREMENT FUND||6,800||102|
|CITADEL ADVISORS LLC||15,217||230|
|ROYAL BANK OF CANADA||822||12|
|Artal Group S.A.||200,000||3,012|
|DEUTSCHE BANK AG\||8,041||120|
|PIEDMONT INVESTMENT ADVISORS LLC||88||1|
|Partner Fund Management, L.P.||826,352||11,458|
|Ameritas Investment Partners, Inc.||415||6|
|BAILLIE GIFFORD & CO||3,803,014||57,274|
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Related News Stories
China’s Hillhouse Capital Group, an equity investment firm, has a new fund, Hillhouse Fund IV, with $10.6 billion ready to invest. The close of this new fund makes it the biggest capital raise by a private-equity company in Asia. (3-0)
Unity Biotechnology saw strong gains in the market on Thursday after the CEO appeared on CNBC.
Unity Biotechnology, Inc. (UBX - Free Report) was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company — as the stock is now up 28.6% in the past one-month time frame.
Without a doubt China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates. And it seems that western pharmaceutical companies are making greater inroads there.
After Unity Biotechnology chief executive officer Keith Leonard was on CNBC’s “Power Lunch,” touting the company’s therapeutic approach to longevity and aging, company shares soared almost 18 percent. Trading was halted for volatility, and after it resumed, shares lost some of those gains, eventually ending up about eight percent.
In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. The funding was from Bold Capital, led by Peter Diamandis, Elevian’s founding investor, WTI, Stanford StartX, Longevity Fund, Kizoo Ventures, Thynk Capital and others.
From anti-aging medicines to new the evolution of esports, Citi Research told clients which technologies it believes are the most disruptive in the world today are and how to invest in them.
Nearly four years after first forging a research collaboration, AbbVie and Calico, Google’s life science company, have extended that 10-year pact with another $1 billion pledge to develop therapies associated with age-related diseases, including neurodegeneration and cancer. (0-1)
Something that most everyone does multiple times a day may not be as care-free as initially thought. Taking a selfie with a smart phone can actually be harmful to your skin.
Early biotech company valuations are a type of voodoo made up of interesting ideas, talented management, investor enthusiasm and wishful thinking. How to explain UNITY Biotechnology, which wants to help you stay young until you die? The company has raised $222 million in venture capital, raised $85 million in an initial public offering (IPO) in May, and has a value of $700 million. All without having a product to sell. (0-1)
as of ET